Nyxoah Reports Preliminary Q3 2026 Results and Adjusts 2026 Revenue Guidance

Third Quarter 2026 — Preliminary Sales and Market Metrics Financials Global net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second quarter of 2026 U.S. net revenue is expected to be approximately €6.7 million in the third quarter of 2026, which reflects 29% sequential growth over the second quarter of 2026 Leading U.S. commercial indicators 80 new surgeons trained in Q3, bringing the total to 342 surgeons trained 53 new accounts activated in Q3, bringing the total to 233 active high-volume accounts 447 patients actively under prior authorization entering Q4 Clinical and Regulatory ACCCESS U.S. pivotal study met its co-primary efficacy endpoints and its safety endpoints in Complete Concentric Collapse (CCC) patients, with a 12-month AHI responder rate of 77.2% (p<0.001) and zero device- and procedure-related serious adverse events Submitted a premarket approval (PMA) supplement to the FDA to expand Genio’s U.S. indication to CCC patients under Breakthrough Device Designation Complete 12-month ACCCESS dataset presented at the International Surgical Sleep Society (ISSS) annual meeting, October 15-16, 2026 Liquidity As of September 30, 2026, cash, cash equivalents and financial assets are expected to be approximately €77.0 million. Revenue Guidance for the Full Year 2026 The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.